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Cervical cancer is one of the most common ma-
lignancies in developing countries. External beam 
radiation therapy (EBRT) to a dose of 45 to 50.4 
Gy in 25 to 28 fractions with concurrent chemo-
therapy followed by brachytherapy (BT) to a dose 
of 6 to 9 Gy per fraction in 2 to 4 fractions is the 
standard care for locally advanced cervical cancer. 
Traditionally, carcinoma of the uterine cervix was 
staged clinically, but now radiological methods are 
incorporated in assigning stage to the disease due to 
their impact on treatment [1]. Moreover, metastasis 
to the pelvic lymph nodes (PLNs) is one of the most 
important prognostic factors which has also been 
included in the FIGO staging [2]. Some retrospec-
tive studies have shown only minimal or no benefit 
in terms of local control and overall survival with 
dose escalation using EBRT [3]. The dose contribu-
tion to the pelvic nodes from brachytherapy is gen-
AbstrAct
background: pelvic lymph node (pLN) metastasis has been included in the FIGO staging, so there is a need to determine 
the dose contribution from brachytherapy to ascertain the total delivered dose to the pelvic lymph nodes in cervical cancer. 
The aim of the study was to calculate the equivalent dose in 2 Gy (eQD2) of the pelvic lymph nodes (pLNs) based on volume 
prescription using three applicators.
Materials and methods: Forty-one patients who had undergone external beam radiotherapy followed by brachytherapy 
using tandem ovoids (TO), tandem ring (Tr) and TO + free hand interstitial needles (TO + Fh) applicators were taken for this 
study. 26 Gy in 4 fractions was prescribed to hrcTV. The external iliac node (eLN), internal iliac node (ILN) and obturator (OBT) 
were contoured and the median eQD2 of the lymph nodes was calculated.
results: The median bilateral eQD2 values of eLN were 1.55 Gy (Tr), 1.75 Gy (TO), 1.9 Gy (TO + Fh), of ILN these were 2.57 Gy 
(Tr), 3.27 Gy (TO), 3.04 Gy (TO + Fh), and of OBT these were 3.69 Gy (Tr), 4.46 Gy (TO), 4.69 Gy (TO + Fh), respectively. The total 
median eQD2 values of Tr, TO and TO + Fh were 52.71 Gy, 53.03 Gy, and 53.88–62.73 Gy, respectively.
conclusion: Our study calculated the median eQD2 to the pelvic lymph nodes using three types of applicators in brachyther-
apy. This could serve as reference to decide on the eBrT boost dose while treating patients with enlarged pelvic lymph nodes.
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erally neither documented nor reported because it 
constitutes a very small part of the prescribed dose. 
Furthermore, there are no standardized guidelines 
that determine the total dose required to achieve 
a complete tumor response in the nodal regions. 
Considering its prognostic significance and the ab-
sence of consensus, there is a need to determine the 
dose contribution from brachytherapy to ascertain 
the total delivered dose to the pelvic lymph nodes 
in cervical cancer.
Intracavitary brachytherapy (ICBT) involves place-
ment of central tandem in the uterine cavity along 
with the ovoids or ring in the vaginal fornices. But in 
cases where there is minimal involvement of the para-
metrium beyond the medial half of the lateral pelvic 
wall and cervical os could be sounded, intracavitary 
brachytherapy with free hand interstitial needles can 
be used. This type of application is regarded as intra-
cavitary + interstitial brachytherapy [4].
BT has undergone a paradigm shift from X-ray 
based planning to image guided planning using 
computed tomography (CT) or magnetic resonance 
imaging (MRI). With the advent of image guided 
brachytherapy, it has become easier to delineate the 
target and organs at risk which has, in turn, helped 
in improving local control and minimizing long 
term side effects [5]. Most centres across the globe 
use the conventional point based prescription and 
in literature there are few studies that estimate the 
dose contribution to PLNs in brachytherapy using 
point based prescription.
The aim of the study was to calculate the equiv-
alent dose in 2 Gy (EQD2) to the external iliac 
lymph node (ELN), the internal iliac lymph node 
(ILN) and the obturator (OBT) group of lymph 
nodes using CT based high dose rate (HDR) BT 
with three different applicators: tandem and ovoid 
(TO), tandem and ring (TR), tandem and ovoid 
with free hand interstitial needles (TO + FH) using 
volume based prescription.
Materials and methods
With institutional ethical board clearance, 41 cer-
vical cancer patients from stage IB2 to IIICr1 who 
underwent BT from January 2018 to January 2019 
treated at a tertiary care hospital (Ramaiah Medical 
College Hospital) were included in this retrospec-
tive study. All patients underwent biopsy from the 
growth, complete blood count, renal function tests, 
liver function tests, echocardiogram and contrast 
enhanced CT scan of the abdomen and pelvis. 
external beam radiotherapy (eBrT) 
Patients were treated with EBRT to a dose of 
45 Gy in 25 fractions using the three dimensional 
conformal radiation therapy (3DCRT) technique 
or intensity modulated radiation therapy (IMRT) 
on 6MV Elekta Agility Linear accelerator with con-
current weekly cisplatin chemotherapy. Bladder, 
rectum, bowel and bilateral femoral heads were 
contoured as organs at risk (OARs). The planning 
target volume included the entire uterus, bilateral 
parametria and upper half or entire vagina depend-
ing on the extent of the disease along with bilateral 
common iliac, external iliac, internal iliac, obtura-
tor and presacral group of lymph nodes that were 
included up to the S2–S3 junction. The OARs dose 
constraints were V45 less than 50% for the bladder, 
rectum and less than 5% for femur, respectively. 
195cc volume of the bowel bag should receive less 
than 45 Gy. The PTV should receive more than 95% 
of the prescription dose. Those patients who had an 
enlarged node of more than one centimetre received 
a boost of 5.4 to 9 Gy/3–5 fractions depending on 
the dose to OARs and technique of radiation. 
Brachytherapy details
Patients received brachytherapy in four fractions 
to a dose of 6.5 Gy per fraction around two weeks 
post completion of EBRT.
Patients were examined under anaesthesia to as-
sess the response to EBRT and the type of ICBT 
application was decided based on the examination 
findings. In patients with central disease and re-
tained cervix, TR (arm A) was used. Patients who 
had residual disease confined to medial 1/3rd of the 
parametrium underwent TO (arm B). Patients with 
an unilateral residual parametrium disease beyond 
medial 1/3rd underwent TO + FH (arm C).
CT scan was done after the procedure with 3 mm 
axial slices (Asteion VP). The images were loaded 
into the HDR plus 3.0.8 treatment planning system 
(TPS) based on Task Group (TG-43) algorithm [6]. 
The bladder, rectum, sigmoid and high risk clinical 
target volume (HRCTV) were contoured based on 
Viswanathan et al. CT based contouring guidelines 
[7]. Applicators were digitized and surface con-
trol points were created based on HRCTV. Volume 
based planning was used and manual optimisa-
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tion was done to minimize the OAR doses and to 
achieve the dose intended to D90 HRCTV. Bebig 
Multisource Cobalt based HDR unit (Eckert and 
Ziegler, Germany) was used to execute the treat-
ment on two consecutive days with a six-hour gap 
between two fractions.
Dosimetric analysis
In addition to the targets and OARs, the pelvic 
lymph nodes were contoured by a radiation oncolo-
gist according to the consensus guidelines formu-
lated by Chua et al. [8]. The ELN, ILN, OBT group 
of lymph nodes were contoured for each patient 
bilaterally. The ELN group was contoured crani-
ally from the L5/S1 junction or two cm above the 
top of the applicator, whichever is inferior, caudally 
up to the superior femoral head, a seven mm mar-
gin around the vessels, was given, except anteriorly 
where a 10 mm margin was used. The ILN group 
was contoured cranially from the L5/S1 junction or 
two cm above the top of the applicator, whichever 
is inferior, caudally up to the termination of the 
internal iliac vessels, a seven mm isotropic margin 
was given around the vessels. The OBT group was 
contoured from the commencement of the gap be-
tween the ELN and ILN regions and connecting 
the two regions with a seven mm margin around 
vessels up to the obturator foramen. All the lymph 
node contours were trimmed from the OARs. Fig-
ures 1–3 show the axial sections of the contours of 
Figure 1. axial and 3D window of Tandem and ring application
Keys:  Right external Left external Right obturator Left obturator Right internal Left internal
Figure 2. axial and 3D window of Tandem and ovoid application
Keys:  Right external Left external Right obturator Left obturator Right internal Left internal
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the pelvic lymph node groups for three different 
applicators. 
The mean dose to each nodal group was docu-
mented for all three arms. The cumulative median 
dose to each lymph node group was calculated and 
tabulated. The equivalent dose to 2 Gy (EQD2) was 
calculated using the below formula:
EQD2= nd[(1 + d/α/β)/(1 + 2/α/β)]
n — number of fractions; d — dose per fraction; 
α/β — 10 for tumor.
statistical methods
The values were tabulated and analysed using 
SPSS version 18.0 software (SPSS Inc., IBM, Chica-
go, USA). Kruskal Wallis Test was used to compare 
the median EQD2 of the pelvic lymph nodes across 
the three arms. A Friedman test was used to com-
pare point B EQD2 and median EQD2 to 2cc pelvic 
lymph nodes for all the applicators. A Spearman 
correlation coefficient test was used to study the 
correlation between point B EQD2 and the median 
EQD2 to 2cc pelvic lymph nodes. The values were 
considered statistically significant when the p value 
was less than 0.05.
results
Patient characteristics are shown in Table 1 and 
the median age was 55 years (35–70). Twenty-nine 
patients had stage IIA–IIB, nine patients had stage 
IIIB, two patients had stage III Cr1 and one pa-
tient had stage IB. Among 41 patients in our study, 
15 patients underwent ICBT with TR (arm A), 15 
patients underwent ICBT with TO (arm B) and 
11 patients underwent with TO + FH ( arm C) of 
whom nine patients had stage IIIB and two patients 
had stage IIICr1.
Table 2 summarizes the median EQD2 to point 
B and 2cc of the pelvic lymph nodes for three dif-
ferent applicators. 
Figure 4 shows the Box-and-Whisker plot of the 
distribution of EQD2 to 2cc pelvic lymph nodes 
and point B EQD2 in the three arms. There is no 
significant difference between the arms in terms 
of median EQD2 to 2cc of bilateral pelvic lymph 
nodes [EXT (p = 0.144); INT (p = 0.747); OBT 
(p = 0.608)].
Subsequently, the median EQD2 of the bilateral 
ELN, ILN and OBT nodes were compared with 
table 1. patient characteristics


















Tandem and ring 
Tandem and ovoid




Figure 3. axial and 3D window of Tandem ovoid with free hand interstitial needles
Keys:  Right external Left external Right obturator Left obturator Right internal Left internal
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median point B EQD2 for all the applicators. Point 
B EQD2 is significantly different from the median 
EQD2 to the ELN and ILN group (p value < 0.001), 
but no such difference is seen for the OBT group 
(p value = 0.574). The correlation coefficients be-
tween point B and the D2cc of the pelvic lymph 
nodes are greater than 0.8 in the TO arm, between 
0.59 to 0.83 in the TR arm and less than 0.4 in the 
TO + FH arm. 
Table 3 depicts the total EQD2 for three applica-
tors obtained by combining EBRT and BT EQD2.
Discussion
Locally advanced cervical cancers are treated 
with definitive chemoradiation followed by brachy-
therapy. The incidence of pelvic lymph node me-
tastases for FIGO stage IIA is 10–45%, 26–62% for 
table 2. Median equivalent dose in 2 Gy (eQD2) to point B and D2cc of pelvic lymph nodes for three different applicators 
(Krushkal Wallis Test)
Parameters
Tandem and Ring  
(n = 15)
Median (range)
Tandem and ovoid  
(n = 15) 
Median (range)






External lymph nodes (bilateral)
Volume [cc] 19.75 (11.5–28.25) 21.45 (11.15–42.4) 23.75 (12.8–28.85)
eQD2 [Gy] 1.55 (1.45–1.76) 1.75 (1.19–2.16) 1.9 (1.62–2.25) 3.872 0.144
Internal lymph nodes (bilateral)
Volume[cc] 31.8 (23.85–54.15) 33.4 (22.85–58.65) 27.95 (14.55–32.35)
eQD2 [Gy] 2.57 (2.45–3.25) 3.27 (2.3–4.41) 3.04 (2.52–3.48) 0.583 0.747
Obturator (bilateral)
Volume [cc] 14.05 (8.3–22.9) 14.7 (10.55–28.45)
16.55
(12–24.35)
eQD2 [Gy] 3.69 (3.15–5.12) 4.46 (3.05–5.74) 4.69 (3.97–5.22) 0.995 0.608
Point b




Figure 4. The Box-and-Whisker plot of equivalent dose in 2 Gy (eQD2) to pelvic lymph nodes. A. external iliac; b. Internal iliac; 
c. Obturator; D. point B. The middle horizontal line represents the median eQD2 and the upper and lower bounds of the box 
represent the 75th and the 25th centile of eQD2
a B
c D
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stage IIB , 39–59% for stage IIIA, and 39–88% for 
stage IIIB/IV according to some surgical series [9]. 
The aim is to deliver a cumulative EQD2 dose of 
80-90 Gy to primary tumor using BT, after EBRT, 
dose of 45 to 50.4 Gy, respectively [10]. However, 
dose to the pelvic nodes is less certain with BT. This 
study is an effort to determine the median dose to 
the nodal regions using three different applicators 
which could help in estimating EBRT boost dose. 
Conventionally, dose to the lymph nodes for ICBT 
is reported by point B and the reference points of 
the lymphatic trapezoid. Point B dose corresponds 
to the dose to the obturator lymph nodes which 
constitute the first echelon group in cervical can-
cers.
Similar studies have been done by Chua et al. 
[8], Lee et al. [11], Lee Y et al. [12] and Matsukawa 
et al. [13], where they did CT based planning but 
prescribed to point A. 
Chua et al. studied the dose to the pelvic lymph 
nodes using two dose fractionation schedules 
(5 and 6 Gy per fraction) on 40 patients. With 
a brachytherapy dose of 5 Gy to point A, the mean 
EQD2 doses received by the EI, II and OB groups 
were 0.71, 1.04, and 1.27 Gy, respectively. With 
a brachytherapy dose of 6 Gy, the mean EQD2 dos-
es received by the EI, II, and OB groups were 1.08, 
1.49, and 1.77 Gy, respectively [8]. In our study, 
using volume based prescription to a dose of 6.5 
Gy per fraction, the median EQD2 ranged between 
3.92–5 Gy for point B, 1.78–2.16 Gy for the ELN 
groups, 2.88–3.56 Gy for the ILN groups and 4–5.2 
Gy for the OBT groups across the three arms.
Lee et al. have reported in their study on the 
correlation coefficients between point B and the 
dosimetric parameters of the pelvic lymph nodes. 
They found that D2cc to the obturator is not sig-
nificantly different from the point B dose. They 
concluded point B is a poor surrogate for the pelvic 
lymph nodes (PLNs) [10]. Similarly, in our study 
we observed the point B dose was not significantly 
different from dose to the OBT nodes across all 
three arms. 
Lee et al. in their study showed that the total 
EQD2 among the lymph node groups varies from 
4.1% to 9.5% of the prescribed dose and the OBT 
group was receiving more dose compared to other 
groups [11]. In our study, we observed that the 
total median bilateral EQD2 of BT varied from 7% 
to 20% of the prescribed dose across all arms using 
volume based prescription. 
Matsukawa et al. correlated dose to point B with 
dose to the pelvic lymph nodes using two applica-
tors used in ICBT. They found that the dose de-
livered to point B and the PLN groups were not 
significantly different between TO and tandem and 
cylinder [12]. Similarly, we observed there was no 
difference in the median EQD2 to the pelvic lymph 
nodes across the three applicators. 
There is a wide heterogeneity in EBRT boost 
dose to the enlarged nodes, so there is a need to de-
termine the total lymph node dose, which includes 
EBRT and brachytherapy dose, to obtain complete 
tumour response in the nodal regions. Ramlov et 
al. in their study analysed 139 patients from the 
EMBRACE data. Median nodal boost dose was 62 
Gy EQD2 (53–69 Gy EQD2). No patients had per-
sistent nodal disease, but six patients recurred in 
a boosted node. Their study did not indicate any 
improved lymph node control with higher boost 
doses and concluded that there was no benefit of 
delivering a total lymph node dose beyond 60 Gy 
EQD2 [13]. A study by Ariga et al. tried to deter-
mine EBRT boost prescribing a median dose of 56 
Gy to metastatic nodes. They found that five of 57 
patients had recurred in boosted nodes [14]. Simi-
lar study by Grigsby et al. analysed different boost 
doses according to nodal size. A median dose of 
67.2 Gy was delivered. Only five of 132 patients 
recurred within a boosted node [15]. Neither of the 
studies found a significant relation between nodal 
size and failure. From the above studies, we can 
table 3. Total equivalent dose in 2 Gy (eQD2) of three applicators obtained by combining external beam radiation therapy 
(eBrT) and brachytherapy (BT) eQD2
Applicator EBRT [Gy] BT [Gy] Total EQD2 [Gy]
Tandem and ring 44.25 8.51 52.71
Tandem and Ovoid 44.25 8.78 53.03
Tandem Ovoid + Freehand 44.25–53.1 9.63 53.88–62.73
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infer that nodal recurrence post radiation therapy 
does not depend on nodal size at presentation and 
there is no benefit of boosting the nodal regions 
beyond 60 Gy. 
In our study, the total median EQD2 to the 
lymph nodes are arm A-52.71 Gy, arm B-53.03 Gy 
and arm C-53.88-62.73 Gy. This could help in de-
ciding the EBRT boost dose as there is no difference 
in total EQD2 using different applicators.
The strength of our study is using volume based 
prescription; we documented dose to the nodal 
regions for three different applicators of TR, TO 
and TO + FH. The limitation of our study is that 
it is a dosimetric analysis in which the number of 
patients is quite low and further clinical follow up 
is required. Also, there is a need for standardised 
guidelines for dose prescription to gross pelvic 
lymph nodes.
conclusion
Our study determined the median EQD2 to the 
pelvic lymph nodes using volume based prescrip-
tion across three types of applicators in brachy-
therapy. Although there is no significant difference 
among the applicators, there is an appreciable con-
tribution from brachytherapy to the pelvic nodal 
regions. This could serve as reference to decide on 
the EBRT boost dose while treating patients with 
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